Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of Abbott Laboratories are down 1.55% at $101.89. The company is worth $176.31B, number 86 out of 300 on our list.
Over the past 52 weeks it has traded between $81.39 and $132.39, so it sits 23.0% below the top of that range. Holders are behind 22.1% over twelve months, but up 13.4% across the last three months.
On the chart it has slipped under both the 50-day ($106.73) and 200-day ($103.92) moving averages; RSI is 43, and the last 30 sessions moved at roughly 20% annualized volatility.
In the quarter ended Jun 2026 the company brought in $12.59B of revenue, up 13.0% from a year earlier, with $928.00M of net profit (a 11.6% margin).
Buyers are paying 33.0 times trailing earnings, 18% above its five-year average of 27.9. The median for its industry group is 23.8.
15 analysts follow the stock and the average call is "buy". The mean target, $124.33, sits 22.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Abbott makes medical devices, diagnostics, nutrition products and branded generic drugs. Its best-known lines include FreeStyle Libre glucose sensors, heart devices and infant formula.
What tends to move it. Investors follow continuous glucose monitor growth, device launches and how much of the pandemic-era testing revenue is still left to roll off.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -4.1% | Bearish |
| Price vs 50-day average | -4.5% | Bearish |
| Price vs 200-day average | -2.0% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 43.1 | Bearish |
| MACD (12,26,9) | -1.46 | Bearish |
| Bollinger band position | 23% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Above its usual level · 69th percentile, 5-year average 27.9x
#2186 of 2978 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 7th percentile, 5-year average 4.9x
#3802 of 5303 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 6th percentile, 5-year average 4.6x
#3455 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$63.71M (9 inflow days, 11 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 11.2% a year.
$101.89 is the latest print for ABT, a move of -1.55% against yesterday's close of $103.49. Today's low and high so far: $101.75 and $104.22.
Equity value comes to $176.31B at the current price. By that measure it is number 86 of the 300 names in our coverage.
Buyers pay 33.0 times the last twelve months of profit (EPS $3.72). Averaged over five years the multiple has been 27.9, and today's level ranks in the 69th percentile of its own history.
The year's floor is $81.39 and the ceiling $132.39. Shares are 23.0% away from that ceiling.
It does. Payouts over the past twelve months work out to a 2.39% yield; the latest ex-dividend date was July 15, 2026.
Of 15 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $124.33, with the most cautious at $112.00 and the most optimistic at $135.00.
Abbott makes medical devices, diagnostics, nutrition products and branded generic drugs. Its best-known lines include FreeStyle Libre glucose sensors, heart devices and infant formula.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.